Peringatan Keamanan

Oral, mouse LD50 = 3700 mg/kg; Intravenous, mouse LD50 = 621 mg/kg; Oral, rabbit LD50 = 1300 mg/kg. Side effects include itching, burning, skin rash, redness, swelling, or other sign of irritation not present before use of this medicine and long-term use of sulfonamides may cause cancer of the thyroid gland.

Sulfanilamide

DB00259

small molecule approved

Deskripsi

Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.

Struktur Molekul 2D

Berat 172.205
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Sulfonamides are absorbed through the vaginal mucosa. There are no pharmacokinetic data available describing how much of an intravaginal dose reaches the systemic circulation.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

67 Data
Prilocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Prilocaine.
Dapsone The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfanilamide.
Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Sulfanilamide.
Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Sulfanilamide.
Tramadol The metabolism of Tramadol can be decreased when combined with Sulfanilamide.
Magnesium The serum concentration of Magnesium can be decreased when it is combined with Sulfanilamide.
Benzylpenicillin Sulfanilamide may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.
Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Sulfanilamide.
Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Sulfanilamide.
Estetrol The therapeutic efficacy of Estetrol can be decreased when used in combination with Sulfanilamide.
Finerenone The serum concentration of Finerenone can be increased when it is combined with Sulfanilamide.
Belzutifan The serum concentration of Belzutifan can be increased when it is combined with Sulfanilamide.
Insulin human The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin human.
Insulin lispro The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin lispro.
Insulin glargine The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin glargine.
Insulin pork The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin pork.
Insulin aspart The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin aspart.
Insulin detemir The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin detemir.
Insulin glulisine The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin glulisine.
NN344 The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with NN344.
Insulin beef The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin beef.
Insulin degludec The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin degludec.
Insulin argine The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin argine.
Insulin peglispro The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin tregopil.
Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Sulfanilamide.
Enzalutamide The serum concentration of Enzalutamide can be increased when it is combined with Sulfanilamide.
Chloroprocaine The therapeutic efficacy of Sulfanilamide can be decreased when used in combination with Chloroprocaine.
Lidocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Procaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Benzocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Quinisocaine.
Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Sulfanilamide.
Cisatracurium Sulfanilamide may increase the neuromuscular blocking activities of Cisatracurium.
Clozapine The serum concentration of Clozapine can be increased when it is combined with Sulfanilamide.
Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Sulfanilamide.
Ambroxol The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Ambroxol.
Fecal microbiota The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Sulfanilamide.
Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Sulfanilamide.
Gepirone The serum concentration of Gepirone can be increased when it is combined with Sulfanilamide.
Insulin icodec The risk or severity of hypoglycemia can be increased when Sulfanilamide is combined with Insulin icodec.

Target Protein

Dihydropteroate synthase folP

Referensi & Sumber

Synthesis reference: Donald R. Randell, Emyr Phillips, "Anthraquinone sulphonamide compounds and preparation." U.S. Patent US4276224, issued May, 1937.
Artikel (PubMed)
  • PMID: 16997145
    Nzila A: Inhibitors of de novo folate enzymes in Plasmodium falciparum. Drug Discov Today. 2006 Oct;11(19-20):939-44. Epub 2006 Sep 7.

Contoh Produk & Brand

Produk: 4 • International brands: 1
Produk
  • Avc
    Cream • 15 g/100g • Vaginal • US • Approved
  • Avc Cream - 15%
    Cream • 15 % • Vaginal • Canada • Approved
  • AVC Vaginal
    Cream • 15 g/100g • Vaginal • US • Approved
  • AVC Vaginal
    Cream • 15 g/100g • Vaginal • US • Approved
International Brands
  • Streptocid

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul